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ABSTRACT 
Background: Influenza is a respiratory illness caused by three different viruses: type A, 
B, or C. Influenza has a large impact on morbidity and mortality globally with an estimated 
attack rate at 5-10% in adults and 20-30% in children. The Influenza vaccine is the most 
effective way to prevent Influenza. The purpose of this epidemiologic study is to determine the 
efficacy of the Influenza vaccines administered between 2013 and 2015, and to address public 
misconceptions concerning the safety of the vaccine. 
Methods: This case control study of adult patients took place at University of Pittsburgh 
Medical Center Mercy Hospital. The study included 306 adult patients with respiratory illnesses 
who were admitted to the hospital during 2013-2015 Influenza seasons. Of these admitted 
patients, 206 tested positive for Influenza while the other 100 patients tested negative and 
therefore served as case controls. Data on each patient were collected via medical records, which 
included vaccination status, demographics such as gender, and outcomes such as length of stay. 
The data were statistically analyzed using SAS v 9.3 software.  
Results: Among Influenza positive cases during the 2013-2014 Influenza season, 34.4% 
were vaccinated and 55.6% were between the ages 51 and 79. Among Influenza positive cases 
during the 2014-2015 season, 64.6% were vaccinated and 57% were between the ages 51 and 79. 
Among Influenza negative cases during both Influenza seasons, 66.7% were vaccinated and 
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56.3% were between the ages 51 and 79. Importantly, as a general finding, those patients who 
received Influenza vaccination prior to admission were significantly less likely to have Influenza 
(p = 0.0132). Patients who were vaccinated prior to admission were statistically significantly 
older (p = 0.0001) and had higher comorbidity scores (p = 0.0001). 
Conclusions: Influenza vaccination significantly reduces the rate of Influenza positivity 
among inpatients. Patients who are older and have higher comorbidity scores are more likely to 
be vaccinated. The Influenza vaccine is significant to public health because it is cost effective 
and reduces hospitalizations and mortality due to Influenza. This information can be used to 
educate patients and health care workers about the Influenza vaccine and its benefits. 
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1.0  INTRODUCTION 
1.1 GLOBAL IMPACT OF INFLUENZA  
Influenza has a large impact on morbidity and mortality globally with an estimated attack 
rate at 5-10% in adults and 20-30% in children, resulting in about three to five million cases of 
severe illness, and about 250,000 to 500,000 deaths19. Therefore, it is essential to better 
understand and investigate the effects of Influenza on global public health in order to decrease 
these rates.  
1.2 INFLUENZA EPIDEMIOLOGY 
In order to effectively prevent individuals from getting Influenza, understanding what the 
causative infective agent is and how it causes illness is essential. Influenza is a respiratory illness 
that is caused by three different viruses, type A, B, or C, with type A being the most severe and 
type C being the least severe29. Type A Influenza can be separated into subtypes based on the 
surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), located on the Influenza 
virus29. Influenza is very pathogenic and difficult to control due to the fact that there are 18 HA 
subtypes and 11 NA subtypes, which can be combined in numerous combinations to create a 
large number of possible Influenza strains29.  
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The Influenza virus is spread through infected air droplets when people cough or sneeze 
and another person inhales the droplets15. Once the virus is in an individual’s respiratory system, 
it will begin to infect cells. Hemagglutinin on the virus recognizes and binds sialic acids on 
carbohydrate side chains of cell-surface glycoproteins and glycolipids, allowing the virus to then 
fuse with the host cell and replicate. Once replication is finished, neuraminidase removes sialic 
acid from the infected cell surface so that the newly made viruses can be released and infect 
more cells14.  
The incubation period for Influenza is about two days19. Once an individual is infected 
they may experience the following symptoms: high fever, cough, headache, muscle and joint 
pain, severe malaise, sore throat and runny nose. These symptoms usually last a week in most 
people but the virus can cause severe illness or even death in people who are at high risk. Those 
in the high risk category includes children younger than two years, adults aged 65 or older, 
pregnant women, those who are immune-compromised and anyone with medical conditions such 
as chronic heart, lung, kidney, liver or blood disease19. An example of a severe illness that these 
groups may experience is bacterial pneumonia that could lead to death or other complications if 
not treated properly12.  
As previously mentioned, Influenza can be spread through infected air droplets. Another 
mode of transmission is through direct contact. For example, if a person’s hand is contaminated, 
touching surfaces that other people come in contact with can facilitate the spread15. This is why it 
is so important for people to wash their hands immediately after covering their mouths when 
coughing and sneezing. Rates of Influenza transmission can be decreased if the population 
practices these simple methods. 
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1.3 PREVENTION 
The most effective way to prevent Influenza and therefore epidemics is by vaccination. 
Influenza vaccinations have been used for more than 60 years and are recommended for anyone 
six months and older21. Vaccination can provide protection in healthy individuals but may be less 
effective in the elderly19. However, the vaccine can still help reduce the severity of the illness 
and mortality risk in the elderly19. High-risk individuals are especially encouraged to get 
vaccinated to help prevent illness or complications from the illness. Unfortunately, the level of 
effectiveness of the annual vaccine is not extremely consistent, and greatly depends on how well 
the vaccine matches the antigenic make-up of the circulating viruses at that given time19. This is 
because Influenza viruses are continuously changing and highly susceptible to antigenic drift21. 
Therefore, the World Health Organization (WHO) updates its vaccine composition 
recommendation biannually to target the three (trivalent) most important virus types that are in 
circulation, which usually includes two subtypes of Influenza A viruses and one B virus19. Most 
recently a quadrivalent vaccine composed of two subtypes of Influenza A viruses and two B 
viruses has been recommended because it is expected to increase protection against Influenza19. 
While there has been some public resistance towards the vaccine, the following data highlights 
the steady increase in vaccinations over the past three years in the United States: 
• 134.5 million doses in 2013-2014 (by 2/28/14) 
• 147.8 million doses in 2014-2015 by (2/6/15) 
• 145.6 million doses in 2015-2016 by (1/15/16)  
Manufacturers have projected they will provide between 171 and 179 million doses of 
vaccine by the end of the 2015-2016 season27.  
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1.4 BENEFITS OF VACCINATION 
There are many benefits of the Influenza vaccine. It not only can provide protection to the 
vaccine recipient, but it can help protect people around them who may be more vulnerable to 
Influenza. This concept is known as ‘herd immunity’. The vaccine can also reduce the number of 
hospitalizations due to Influenza. For example, during both the 2010-2012 Influenza seasons the 
vaccine was associated with a 74% reduction in children’s risk of Influenza-related pediatric 
intensive care unit admission and as well as a 71% reduction in Influenza-related hospitalizations 
in adults of all ages during the 2011-2012 Influenza season21. Moreover, studies have shown that 
the vaccine is also effective for protecting women who are pregnant, as well as their babies for 
up to six months after they are born21. A study showed that the Influenza vaccine given to 
pregnant women was 92% effective in preventing their babies from being hospitalized5.  
1.5 VACCINE EFFECTIVENESS 
As mentioned earlier, the vaccine’s effectiveness relies on which Influenza viruses are 
circulating at the time. The predominating, circulating virus during the 2013-2014 Influenza 
season was Influenza A 2009 H1N1, which was included in the vaccine for that year16. Because 
of this, the vaccine effectiveness was 61% for all age groups1. The predominating, circulating 
virus during the 2014-2015 Influenza season was Influenza A H3N2, which was different from 
the Influenza A H3N2 component of the vaccine. This caused the vaccine effectiveness to only 
be 23%, which caused more hospitalizations and deaths compared to the previous Influenza 
season17. The 2013-2014 Influenza season had 9,586 hospitalizations and 96 laboratory-
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confirmed, Influenza-associated pediatric deaths16. In comparison, the 2014-2015 Influenza 
season had 17,911 hospitalizations and 141 laboratory-confirmed, Influenza-associated pediatric 
deaths17. These data highlight the importance of an effective match between the Influenza 
vaccine and the circulating viruses of a given season.  
Despite the fact that the viral component of the Influenza vaccine was not a strong match 
to the circulating viruses during the 2014-2015 Influenza season, the vaccine still proved 
beneficial. There were an estimated 1.9 million Influenza-associated illnesses prevented, 966,000 
Influenza-associated medical visits prevented, and 67,000 Influenza hospitalizations prevented10. 
The vaccine still provided protection against vaccine-like Influenza A (H3N2) viruses that had 
not significantly changed due to antigenic drift and against Influenza B viruses that predominated 
late in the season17. The more people vaccinated will generally decrease the number of 
hospitalizations and deaths due to Influenza. A modeling study conducted for the 2013-2014 
Influenza season concluded that if the vaccination rates were improved from 40% to 70%, 
another 5.9 million Influenza illnesses, 2.3 million medically attended illnesses, and 42,000 
Influenza hospitalizations could have been prevented24.  
1.6 SURVEILLANCE 
The Department of Health in Pennsylvania has an Influenza surveillance system that 
keeps a record of the number of reported cases of Influenza that occur each week25. The system 
is used more often and looked more closely at during the fall and winter seasons. The official 
Influenza surveillance period begins in October and ends in May of the following year. Reported 
cases are only those that have had a positive laboratory test for Influenza, which is done by a 
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rapid test, direct fluorescent antibody assay (DFA), polymerase chain reaction (PCR), or culture. 
A large number of Influenza cases go unreported because many individuals do not go to the 
doctor and/or do not get tested. It is estimated that between 5 to 20% of Pennsylvanians contract 
Influenza on any given year and the number of deaths due to Influenza-related complications 
range between120 to 2,000 annually25. From October 3rd, 2015 to March 12th, 2016 there were 
10,965 cases of Influenza, 8,676 of which were caused by Influenza A viruses, 2,178 by 
Influenza B viruses, and 111 by unknown viruses25.  
1.7 LOCAL INFLUENZA DATA 
It is also important to review Influenza on a local level. Allegheny Health Department 
reported that as of March 12, 2016 there have been 739 cumulative cases, 65 cumulative 
hospitalizations, and three deaths. These numbers are substantially lower than the previous 
Influenza season, which recorded 4,917 cumulative cases, 732 cumulative hospitalizations, and 
23 cumulative deaths3. The 739 cumulative cases for this current Influenza season can be broken 
down into 646 cases being caused by Influenza A viruses and 93 being caused by Influenza B 
viruses25. While the complete data set from this Influenza season is not yet complete, the current 
trend suggests a promising improvement over the previous season. 
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1.8 RESPIRATORY VIRAL PANEL TEST 
As mentioned before, reported cases are only those that have had a positive laboratory 
test for Influenza. One of those tests, the direct fluorescent-antibody assay (DFA), offers a rapid 
turnaround time for results but is labor-intensive and subjective, and also requires trained 
technologists and specific monoclonal antibodies. Because of these limitations, a multiplex PCR 
assay has been developed, called the respiratory virus panel (RVP) test. This can detect several 
different viruses, including conventional respiratory viruses, common cold viruses, and newly 
emerging respiratory viruses22. The assay works in multiple steps beginning with a multiplex 
PCR using 14 primer pairs, followed by a multiplex target-specific primer extension (TSPE) 
using 21 primer pairs, to detect and identify 20 different virus types and subtypes in a single test. 
This test only requires 5 hours and when contamination precautions are taken, there is a low risk 
for false positives22. In one study, researchers concluded that the test was more sensitive than the 
standard DFA method and could additionally detect other respiratory virus infections that would 
otherwise go undetected by methods commonly used11. This test could also be a very important 
tool to use for global surveillance of emerging or reemerging respiratory viruses, such as SARS 
or the avian Influenza virus H5N122. 
1.9 TREATMENT OPTIONS 
Even though the Influenza vaccine is the best way to prevent a person from getting 
Influenza, in the event of sickness the best treatment option currently available is use of antiviral 
prescription drugs. The CDC recommends taking these drugs within the first 48 hours of 
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infection31. These drugs work by binding to the neuraminidase protein on the virus and not 
allowing it to replicate. Three commonly used FDA approved Influenza antiviral drugs include 
Tamiflu® (generic name oseltamivir), Relenza® (generic name zanamivir), and Rapivab® 
(generic name peramivir)31. These drugs can decrease symptoms and length of illness by one to 
two days. Importantly, they can also prevent serious Influenza complications, which is an 
essential benefit for high-risk patients. Considering the fact that these antiviral drugs can 
decrease Influenza symptoms, they can have a positive financial impact by limiting Influenza 
associated hospitalization visits and stays.  
One major problem with antiviral drugs is antiviral resistance, where the virus can 
selectively mutate to become resistant to their effects31. While the three antiviral drugs listed 
above are still effective at targeting current circulating Influenza viruses the two other antiviral 
drugs, amantadine and rimantadine, are not used in the United States anymore because of the 
development of Influenza resistance31. Because of this fact, the CDC constantly monitors 
circulating Influenza viruses for evidence of antiviral resistance through a variety of laboratory 
testing methods31.  
1.10 HEALTH CARE INFECTION PREVENTION EFFORTS 
Environments where people live in close contact with one another, such as nursing homes 
or college dorms can contribute to the spread of the Influenza virus and therefore put residents at 
a higher risk of infection. According to the Centers for Medicare & Medicaid Services (CMS), 
there have been 7,300 Influenza deaths in nursing homes annually along with $173 million in 
inpatient Medicare spending8. Today, most nursing home residents receive the Influenza vaccine. 
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However, the vaccine is known to be less effective for elderly and immune-compromised 
individuals. After observing case reports of outbreaks of Influenza in certain nursing homes, it 
was strongly suggested that health care workers were transmitting the virus to the residents7. For 
these reasons, it is extremely important for health care workers in nursing homes to get 
vaccinated. One study estimated the vaccination rates in nursing home employees to range from 
33% to 61%28. In another study that surveyed 37 nursing homes in Florida, Georgia and 
Wisconsin, the vaccination rates were 36.4%, 58.5%, and 73.4% respectively8. Researchers 
attributed these rates to the employee’s beliefs such as the effectiveness of the vaccine. They 
reported that vaccination rates increased 12 percentage points when employees believed that the 
vaccine does not cause Influenza8. 
Considering the impact that vaccinated employees have on their nursing home residents, 
it is strongly suggested that employee vaccinations for Influenza become mandatory. According 
to the CDC the vaccination coverage rate for health care workers was 64.3% during the 2014-
2015 Influenza season and 62.9% during the 2013-2014 Influenza season20. These rates were 
measured during the early months of the seasons and Influenza vaccination rates increased by 9-
12 percentage points by the end of each Influenza season. While these coverage rates are 
impressive, if Influenza vaccine was required by all health care workers, the coverage rates 
would likely be even higher. The American Academy of Pediatrics reported that during the 
2013-2014 Influenza season, 36% of all health care workers, and 58% of hospital workers were 
subjected to a mandatory Influenza vaccination requirement18. They also reported that 500 health 
care facilities nationally have required their health care workers receive an Influenza vaccine. 
Seattle’s Virginia Mason Medical Center mandated Influenza vaccinations for all their 
employees in 200518. Employees who were exempt from the vaccine requirement due to medical 
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or religious reasons were required to wear a mask at work during the entire Influenza season. The 
medical center reported 97.6% coverage in the first year. This coverage rate was compared to 
vaccination rates during previous years that were between 29.5% to 54%. This is a great example 
of how effective a mandatory Influenza vaccine policy works to control the disease.  
Locally, University of Pittsburgh Medical Center (UPMC) has implemented a universal 
Influenza immunization policy for every staff member working in a clinical location. This policy 
was put in place in September at the beginning of the 2015-2016 Influenza season30. Employees 
who elected not to receive the vaccine were required to complete an education program on the 
benefits of the vaccine and acknowledge that they understood the risks for themselves and 
others. After this policy was issued, more than 80 percent of the UPMC staff was vaccinated. 
This was a greater than ten percent increase compared to previous Influenza seasons30. UPMC 
offered hundreds of free vaccination clinics at many different locations, which greatly 
contributed to their success in increasing staff immunization30.  
1.11 OBJECTIVE 
The importance of the Influenza vaccine is well recognized, still many people are hesitant 
to get vaccinated and not aware of the benefits. Because of this, the objective of this study was to 
evaluate the effectiveness of the Influenza vaccine through analysis of patients admitted to the 
hospital with respiratory illness. The effect was measured by comparing symptomatic patients 
who tested positive for Influenza to those who tested negative.   
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2.0  METHODS 
2.1 STUDY DESIGN  
This was a case-control study of adult patients at University of Pittsburgh Medical Center 
Mercy and was approved as a Quality Improvement project by UPMC Health System. The cases 
included patients who were admitted to the hospital and had a positive respiratory viral panel 
result during both the 2013-2014 and the 2014-2015 Influenza seasons. Controls included 
patients who were admitted to the hospital and had a negative respiratory viral panel result, 
within the same time frame. We define the Influenza season as running from the beginning of 
November to the end of April. This time frame was chosen after determining the range of months 
that recorded the highest number of Influenza cases by studying data from previous Influenza 
seasons.  
Considering the study’s objective was to evaluate the effectiveness of the Influenza 
vaccine on hospitalized patients, we looked for any demographic and outcome variables that 
could have any influence on the patient getting their vaccine. Some variables included were age, 
race, mortality, and vaccination status. These variables were investigated by collecting data on 
each patient and interpreting the results after the data was statistically analyzed.  
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2.2 DATA COLLECTION 
Data on each patient was obtained via medical records from multiple UPMC databases 
including Cerner (the primary software for patient data), TheraDoc (infection control for all RVP 
data) and McKesson (medical imaging database). Demographic data including age, gender, and 
comorbidities were collected for each patient. Comorbidities were scaled using the Charlson 
Comorbidity Index, which classifies comorbid conditions by predicting mortality26. Patients from 
older age groups, and those with severe clinical conditions, such as a malignant tumor and 
leukemia, registered a higher comorbidity index number, whereas younger patients and those 
with slightly less severe clinical conditions, such as peptic ulcers or mild diabetes, generally had 
a lower comorbidity index number (the Charlson Comorbidity index can be found in Appendix 
B). Outcomes including length of stay (LOS), length of intensive care unit (ICU) stays, ventilator 
use, readmission, and mortality were also collected for each patient. Readmission was 
determined to either be 1-30 days, 60-90 days or more. Mortality was determined to be either 
Influenza related or non-Influenza related. Data on patient vaccination status were also collected, 
which was found in the medical review in the Cerner database. An example of a spreadsheet with 
all variables can be found in appendix A.  
2.3 DATA ANALYSIS  
Once the data was collected and organized into three different Excel spreadsheets, two 
for cases and one for controls, they were statistically analyzed using the SAS v 9.3 statistical 
analysis software. For each demographic and outcome variable, a two by two contingency table 
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of independent and dependent variables was constructed. Fisher’s Exact test was performed for 
every table to observe the statistical significance between variables. This test was also used 
because of the small sample sizes. Because some data variables were categorical, they were not 
normally distributed, so consequently a nonparametric measurement was needed for some of the 
variables. In this instance a Kruskal-Wallis test was performed to observe if variables in the 
contingency tables were significantly different. Lastly, a box and whisker plot of Wilcoxon 
scores were used to display the comparative results. 
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3.0  RESULTS 
A total of 306 patients were included in this study. Out of those 306 patients, 206 
represented the cases and 100 represented the controls. Influenza vaccination status was not 
known for 30 patients and these were therefore excluded from the study, leaving a total of 276 
patients to be analyzed.  
Among Influenza positive cases during the 2013-2014 season, demographic data were as 
follows: 34.4% were vaccinated, 65.6% were not, 55.5% were female, 44.4% were male, 60% 
were Caucasian, 32.2% were African-American, 41.1% were between the ages of 20 and 50, 
55.6% were between the ages of 51 and 79, and 3.3% were 80 or older. The outcome variables 
for these patients were as follows: an average of 5.4 days for LOS, 23.2% stayed in the ICU, 
5.6% required a vent, 60% were readmitted, and 8% died. Among Influenza positive cases during 
the 2014-2015 season, demographic data was as follows: 64.6% were vaccinated, 35.4% were 
not, 64.6% were females, 35% were males, 78% were Caucasian, 22.3% were African-
American, 10.1% were between the ages of 20 and 50, 57% were between the ages 51 and 79, 
and 33% were 80 and up. The outcome variables for these patients were as follows: an average 
of 5.5 days for LOS, 25.3% stayed in the ICU, 2% required a vent, 43% were readmitted, and 
14% died. Among Influenza negative cases (controls) during the two Influenza seasons, 
demographic data was as follows: 66.7% were vaccinated, 33.3% were not, 51.7% were female, 
48.3% were male, 71.3% were Caucasian, 28.8% were African-American, 28.7% were between 
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the ages 20 and 50, 56.3% were between the ages 51 and 79, and 14.9% were 80 and older. The 
outcome variables for these patients were as follows: an average of 7.7 days for LOS, 46% 
stayed in the ICU, 8.2% required a vent, 69% were readmitted, and 32% died. Table 1 lists all 
the results in detail. 
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Table 1. Demographic data broken down by variable and Influenza season 
Variable* 
N=276 
  Influenza Positive 
(13-14) 
 N=90 
     Influenza Positive  
              (14-15) 
               N=99 
Influenza Negative   
(13-15) 
N=87 
Vaccination: Yes 31 (34.4%)           64 (64.6%) 58 (66.7%) 
 Vaccination: No 59 (65.6%)           35 (35.4%) 29 (33.3%) 
        Age (mean & Std Dev)            53 ± 16             70 ± 18 61 ± 18 
      Gender  
         50 (55.5%) Females 
          40 (44.4%) Males 
    64 (64.6%) Females 
       35 (35%) Males 
     45 (51.7%) Females 
      42 (48.3%) Males 
         Race 
      54 (60%) Caucasian 
      29 (32.2%) African-  
            American 
   73 (78%) Caucasian 
    21 (22.3%) African- 
           American  
  57 (71.3%) Caucasian 
   23 (28.8%) African- 
          American 
      LOS (mean & Std Dev)               5.4 ± 8.4 5.5 ± 5.4 7.7 ± 6.1 
          ICU  
Yes: 23 (23.2%) 
No: 67 (74.4%) 
       Yes: 25 (25.3%) 
        No: 74 (74.7%) 
         Yes: 40 (46%) 
          No: 47 (54%) 
Vent Required 
Yes: 5 (5.6%) 
No: 85 (94.4%) 
         Yes: 2 (2%) 
        No: 97 (98%) 
         Yes: 7 (8.2%) 
        No: 78 (91.8%) 
Readmission 
No: 36 (40%) 
1-30 Days: 35 (39%)      
31-60 Days: 13 (14.4%) 
61-90 Days: 6 (7%) 
       No: 56 (57%)     
1-30 Days: 31 (31.3%) 
     31-60 Days: 8 (8%) 
     61-90 Days: 4 (4%) 
No: 27 (31%) 
   1-30 Days: 52 (60%) 
  31-60 Days: 8 (9.2%) 
     61-90 Days: 0 (0%) 
   Deceased 
No: 83 (92%) 
Yes: 7 (8%) 
         No: 85 (86%) 
        Yes: 14 (14%) 
          No: 59 (68%) 
         Yes: 28 (32%) 
*Patients who were determined Unknown for their Influenza vaccination prior to admission were 
excluded from the data.  
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Univariate and multivariate regression analysis was performed to evaluate the presence of 
any particular significant risk factors. A p-value less than 0.05 is considered significant. Patients 
who were vaccinated prior to admission had statistically significantly higher comorbidity scores 
compared to patients who were not vaccinated before being admitted to the hospital (p = 0.0001). 
Table 2 shows the percentages of patients who had a high Charlson score separated by their 
vaccination status and that there was a higher percentage of patients who were vaccinated and 
had a high Charlson index number.  Figure 1 displays the distribution of Wilcoxon scores to 
show that patients who were vaccinated prior to admission and who had a high Charlson score 
had a higher rank compared to patients who did not get vaccinated and who had a low Charlson 
score.  
Table 2. Prior Vaccination by High Charlson Score 
Prior Vaccination High Charlson (Charlson > =5) 
Frequency 
Row Percent 
Column Percent 
No Yes Total 
No 
95 
77.24% 
56.98% 
28 
22.76% 
25.69% 
123 
44.57% 
Yes 
72 
47.06% 
43.11% 
81 
52.94% 
74.31% 
153 
55.43% 
Total 
167 
60.51% 
109 
39.49% 
276 
100% 
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Figure 1. Wilxocon Scores for Charlson Comorbidity Index.  
 
Patients with higher comorbidity index numbers are more likely to receive the Influenza 
vaccine 
 
 
Patients who were vaccinated prior to admission were statistically significantly older in 
age (p = 0.0001). Figure 2 shows that the distribution of Wilcoxon Scores are uneven so the 
Kruskal-Wallis test was used to confirm that older patients were more likely to be vaccinated 
prior to admission (p = 0.0001).   
Prior Vaccination 
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Figure 2. Wilcoxon Scores for Patient ages.  
Older patients are more likely to receive the Influenza vaccine 
 
After performing Fisher’s exact tests using data from the contingency tables, there was no 
statistically significant difference between genders but racial minorities had lower rates of 
vaccination (p = 0.0025). Table 3 shows percentages of prior vaccination between racial groups 
and that African-Americans had lower percentages of vaccinations compared to Caucasians. 
Patients who received Influenza vaccination prior to admission were significantly less likely to 
have Influenza (p = 0.0132). Table 4 shows the number of patients who were positive or negative 
for Influenza and whether or not they were vaccinated prior to admission. There was no 
statistically significant difference between patients who stayed in the ICU, required a vent, were 
Prior Vaccination 
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readmitted on different days, or their mortality. The contingency tables for these variables can be 
found in Appendix B.  
 
   Table 3. Percentage of patients who were vaccinated prior to admission separated by race 
 Race 
Prior Vaccination Caucasian African-American 
No 
N=115 
68 (59%) 47 (41%) 
Yes 
N=142 
112 (79%) 30 (21%) 
  
Table 4. Prior vaccination separated by negative and positive cases of Influenza 
Prior Vaccination Case (Positive Influenza test) 
Frequency 
Row Percent 
Column Percent 
No Yes Total 
No 
29 
23.58% 
33.33% 
94 
76.42% 
49.74% 
123 
44.57% 
Yes 
58 
37.91% 
66.67% 
95 
62.09% 
50.26% 
153 
55.43% 
Total 
87 
31.52% 
189 
68.48% 
276 
100% 
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4.0  DISCUSSION 
The most important observed result was Influenza vaccination reduced the rate of 
Influenza positivity among patients. There were a larger proportion of patients who were 
vaccinated prior to admission, who didn’t get Influenza. In a very similar study, also completed 
at UPMC, the data analyzed demonstrated that the Influenza vaccine was an effective 
intervention that decreased the likelihood of ICU admission in patients hospitalized for Influenza 
with an odds ratio of 0.156. In yet another similar study, researchers were able to conclude that 
hospital admissions caused by Influenza, pneumonia, bronchitis and emphysema were reduced 
by 63% due to the Influenza vaccine4. These three studies, including the present one, indicate 
how critical it is for people to get their Influenza vaccines in order to reduce the risk of illness 
and other Influenza-related complications that could lead to the patient being admitted to the 
hospital.  
During the 2013-2014 Influenza season, the median age of patients who were vaccinated 
for Influenza was 53 while during the 2014-2015 Influenza season, the median age of patients 
who were vaccinated was 70. This difference could be because older patients with medical 
complications are encouraged to get the Influenza vaccine more so by their physician because of 
their increased risk of morbidity if they get Influenza32. In both seasons there were a higher 
percentage of females than males that were vaccinated, and a higher percentage of Caucasians 
vaccinated compared to African-Americans. Overall, there were no significant differences in 
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outcomes related to LOS, patients staying in the ICU, and patients requiring a ventilator between 
the two seasons. Readmission percentages were slightly higher in the 2013-2014 Influenza 
season while death percentages were slightly higher in the 2014-2015 Influenza season. 
Increased readmission during the 2013-2014 Influenza season could have been the result of 
lower vaccination rates (34.4% compared to 64.6%) and the observed increase in deaths during 
the 2014-2015 Influenza season was most likely due to the vaccine ineffective coverage (only 
23%)17 of the circulating viral strains.  
Patients with a higher comorbidity index, individuals with more than one dangerous 
health condition, were more likely to be vaccinated. Older patients were also more likely to be 
vaccinated compared to younger patients. The CDC posted a report that showed similar results in 
other major cities during the 2014-2015 Influenza season. Chicago, New York City, and 
Philadelphia all had an increase in individuals aged 65 and older who received their Influenza 
vaccine with percentages at 62.1%, 58.2%, and 59.2%, respectively2. A lower percentage of 
racial minorities who were vaccinated prior to admission were observed. One study conducted an 
online survey that sampled participants from minority racial backgrounds as well as individuals 
living under the poverty level, to assess their reasons for not getting the Influenza vaccine during 
the 2009-2010 season13. In that study, African-Americans were the most likely racial group to 
have stated that they did not receive the vaccine because it was unavailable to them13. They were 
also the least likely racial group to think the vaccine was safe13. These results could reflect why 
there were a lower percentage of African-American individuals who received their Influenza 
vaccine prior to admission in our study.  
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4.1 LIMITATIONS 
This study had several limitations including being a retrospective study, the small number 
of patients, the limited number of years included and being a single center study. Another 
limitation of this type of study is the potential for inaccurate reporting or documentation of prior 
vaccination by the patient, physician, and/or computer system. The patient being surveyed may 
not be able to accurately recall related details such as the date when they received their Influenza 
vaccine, or they may falsify information intentionally or unintentionally for whatever reason. 
Physicians might enter the information wrongly into the computer system or there may be a 
computer malfunction. This could lead to some errors in the data or skewed results. However, 
this study has many strengths, including the clearly defined cohorts of Influenza positive vs. 
Influenza negative control of patients being admitted to the hospital and undergoing respiratory 
viral panel testing after presenting with a respiratory illness. Moreover, this study addressed 
questions regarding both health care utilization as well as individual patient outcomes.  
4.2 PUBLIC HEALTH SIGNIFICANCE 
The diagnosis and treatment of Influenza can be a long and financially burdening 
experience for most patients. The most precise diagnosis (the RVP test) involves laboratory work 
and takes time to process. The treatment can vary depending on whether the patient was sick 
solely with Influenza or with a further Influenza-associated illness like pneumonia. If the patient 
had an Influenza-associated illness then they might need to be admitted to the ICU and need a 
vent, which could be costly and life threatening. Anti-viral drugs that are issued to patients can 
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be costly and have bad side effects. Influenza can also be a financial burden on an individual 
when they have to stay home from work. These factors can largely affect families with low 
socioeconomic status. For these reasons, it is important to have patients vaccinated against 
Influenza.  
According to a study that measured the disease burden and costs of Influenza in 2003, the 
annual direct medical costs were approximately $10.4 billion, with a projected Influenza 
associated lost of earnings to be estimated at $16.3 billion annually, and a total economic impact 
annually of $87.1 billion23. While part of the costs are due to hospitalizations, the majority is due 
to a loss in productivity resulting from missed workdays and loss of lives23. Importantly, the 
Influenza vaccine can have a positive financial impact on a society considering that the vaccine 
prevented approximately 6.6 million Influenza-associated illnesses during the 2012-2013 season 
and 1.9 million during the 2014-2015 season, while preventing 79,000 hospitalizations and 
67,000 hospitalizations in those seasons respectively9.  
4.3 FUTURE DIRECTION 
The purpose of this study was to observe the effect of the Influenza vaccination on 
patients admitted to the hospital. Additional activities can be done to better understand the results 
of this study. An important direction would be to determine the reason behind the poor rates of 
Influenza vaccinations associated with racial minorities. Such a study could lead to a targeted 
increase the percentage racial minorities being vaccinated. Studies such as the one presented here 
could also be expanded to more locations in the Pittsburgh area to increase the sample size and to 
observe the effects of the Influenza vaccine on more than one hospital.  
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5.0  CONCLUSION 
Influenza vaccination reduced the rate of Influenza positivity among inpatients during the 
2013-2015 Influenza seasons. Patients who were older in age and/or with a higher comorbidity 
index were more likely to have been vaccinated prior to being admitted. There was no difference 
between genders, but racial minorities had a lower rate of vaccination. This information can be 
used to not only motivate and educate patients about the Influenza vaccine and its benefits but 
health care workers at UPMC Mercy as well.   
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APPENDIX A: TABLES AND FIGURES 
 
Figure 3. An example of an excel spreadsheet that was used to collect data on patients 
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Table 5. Contingency table of prior vaccination by sex 
Prior Vaccination Sex 
Frequency 
Row Percent 
Column Percent 
Female Male Total 
No 
71 
57.72% 
44.65% 
52 
42.28% 
44.44% 
123 
44.57% 
Yes 
88 
57.52% 
55.35% 
65 
42.48% 
55.56% 
153 
55.43% 
Total 
159 
57.61% 
117 
42.39% 
276 
100% 
 
 
Table 6. Contingency table of prior vaccination by ICU care 
Prior Vaccination ICU Care 
Frequency 
Row Percent 
Column Percent 
No Yes Total 
No 
90 
73.17% 
47.87% 
33 
26.83% 
37.50% 
123 
44.57% 
Yes 
98 
64.05% 
52.13% 
55 
35.95% 
62.50% 
153 
55.43% 
Total 
188 
68.12% 
88 
31.88% 
276 
100% 
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Table 7. Contingency table of prior vaccination by vent required 
Prior Vaccination Vent Required 
Frequency 
Row Percent 
Column Percent 
No Yes Total 
No 
117 
96.69% 
45.00% 
4 
3.31% 
28.57% 
121 
44.16% 
Yes 
143 
93.46% 
55.00% 
10 
6.54% 
71.43% 
153 
55.84% 
Total 
260 
94.89% 
14 
5.11% 
274 
100% 
 
 
Table 8. Contingency table of prior vaccination by Influenza death 
Prior Vaccination Influenza Death 
Frequency 
Row Percent 
Column Percent 
No Yes Total 
No 
117 
98.32% 
46.99% 
2 
1.68% 
22.22% 
119 
46.12% 
Yes 
132 
94.96% 
53.01% 
7 
5.04% 
77.78% 
139 
53.88% 
Total 
249 
96.51% 
9 
3.49% 
276 
100% 
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Table 9. Contingency table of prior vaccination by readmission 
Prior Vaccination Readmission 
Frequency 
Row Percent 
Column Percent 
1-30 Days 31-60 Days 61-90 Days No Total 
No 
50 
40.65% 
42.37% 
12 
9.76% 
41.38% 
6 
4.88% 
60.00% 
55 
44.72% 
46.22% 
123 
44.57% 
Yes 
68 
44.44% 
57.63% 
17 
11.11% 
58.62% 
4 
2.61% 
40.00% 
    64 
41.83% 
53.78% 
153 
55.43% 
Total 
118 
42.75% 
29 
10.51% 
10 
3.62% 
119 
43.12% 
276 
100% 
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APPENDIX B: COMORBIDITY INDEX TABLE 
Table 10. Comorbidity Index Table 
Weight Clinical Conditions 
1 
Myocardial Infarct 
Congestive Cardiac insufficiency 
Peripheral vascular disease 
Dementia 
Cerebrovascular disease 
Chronic pulmonary disease 
Connective tissue disease 
Slight diabetes, without complications 
Peptic ulcers 
Chronic liver diseases or cirrhosis 
2 
Hemiplegia 
Moderate or severe kidney disease 
Diabetes with complications 
Tumors 
Leukemia 
Lymphoma 
3 Moderate or severe liver disease 
6 Malignant tumor, metastasis 
AIDS 
Age Group Points 
<40 
41-50 
51-60 
61-70 
71-80 
>80 
0 
1 
2 
3 
4 
5 
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